Literature DB >> 20149782

Activation of the A(3) adenosine receptor inhibits fMLP-induced Rac activation in mouse bone marrow neutrophils.

Dharini van der Hoeven1, Elizabeth T Gizewski, John A Auchampach.   

Abstract

Adenosine is released from injured or hypoxic tissues where it exerts numerous anti-inflammatory effects including suppression of neutrophil functions. Although most previous work has implicated the A(2A)AR, we have recently shown that selective activation of the abundantly expressed A(3)AR inhibits neutrophil superoxide production and chemotaxis providing a potential mechanistic explanation for the efficacy of A(3)AR agonists in experimental animal models of inflammation. In this study, we hypothesized that the A(3)AR suppresses neutrophil functions by inhibiting the monomeric GTPase Rac, a central regulator of chemokine-directed neutrophil migration and superoxide production. We found that pre-treating neutrophils with the highly selective A(3)AR agonist CP-532,903 reduced fMLP-induced Rac activation using an ELISA-based assay that detects all three Rac isoforms. CP-532,903 also inhibited fMLP-induced F-actin formation, a downstream effector function of Rac relevant to neutrophil migration, but not activation of ERK1/2 or p38. Pre-treating neutrophils with CP-532,903 did not stimulate cAMP production or alter fMLP-induced calcium transients, implicating that A(3)AR stimulation does not inhibit Rac activation or neutrophil activities by suppressing Ca(2+) signaling, elevating the intracellular concentration of cAMP, or by cross-desensitizing fMLP receptors. Our results suggest that activation of the A(3)AR signals to suppress neutrophil functions by interfering with the monomeric GTPase Rac, thus contributing to the ant-inflammatory actions of adenosine. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20149782      PMCID: PMC2847012          DOI: 10.1016/j.bcp.2010.02.002

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  54 in total

1.  Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics.

Authors:  D C Edwards; L C Sanders; G M Bokoch; G N Gill
Journal:  Nat Cell Biol       Date:  1999-09       Impact factor: 28.824

2.  Signaling requirements for translocation of P-Rex1, a key Rac2 exchange factor involved in chemoattractant-stimulated human neutrophil function.

Authors:  Tieming Zhao; Perihan Nalbant; Mikio Hoshino; Xuemei Dong; Dianqing Wu; Gary M Bokoch
Journal:  J Leukoc Biol       Date:  2007-01-16       Impact factor: 4.962

3.  ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.

Authors:  Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger
Journal:  Science       Date:  2006-12-15       Impact factor: 47.728

4.  Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells.

Authors:  C A Salvatore; S L Tilley; A M Latour; D S Fletcher; B H Koller; M A Jacobson
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

5.  A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury.

Authors:  J E Jordan; V H Thourani; J A Auchampach; J A Robinson; N P Wang; J Vinten-Johansen
Journal:  Am J Physiol       Date:  1999-11

6.  Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.

Authors:  M C Montesinos; J S Yap; A Desai; I Posadas; C T McCrary; B N Cronstein
Journal:  Arthritis Rheum       Date:  2000-03

7.  Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation.

Authors:  D R Ambruso; C Knall; A N Abell; J Panepinto; A Kurkchubasche; G Thurman; C Gonzalez-Aller; A Hiester; M deBoer; R J Harbeck; R Oyer; G L Johnson; D Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils.

Authors:  Dharini van der Hoeven; Tina C Wan; John A Auchampach
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

9.  The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel.

Authors:  Tina C Wan; Zhi-Dong Ge; Akihito Tampo; Yasushi Mio; Martin W Bienengraeber; W Ross Tracey; Garrett J Gross; Wai-Meng Kwok; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2007-09-28       Impact factor: 4.030

Review 10.  Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

Authors:  György Haskó; Joel Linden; Bruce Cronstein; Pál Pacher
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  6 in total

Review 1.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

2.  Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.

Authors:  Zubair Shah; Thomas Kampfrath; Jeffrey A Deiuliis; Jixin Zhong; Colleen Pineda; Zhekang Ying; Xiaohua Xu; Bo Lu; Susan Moffatt-Bruce; Rekha Durairaj; Qinghua Sun; Georgeta Mihai; Andrei Maiseyeu; Sanjay Rajagopalan
Journal:  Circulation       Date:  2011-10-17       Impact factor: 29.690

Review 3.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

4.  A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils.

Authors:  Dharini van der Hoeven; Tina C Wan; Elizabeth T Gizewski; Laura M Kreckler; Jason E Maas; Jordan Van Orman; Katya Ravid; John A Auchampach
Journal:  J Pharmacol Exp Ther       Date:  2011-06-21       Impact factor: 4.030

5.  Milk fat globule-epidermal growth factor-factor VIII-derived peptide MSP68 is a cytoskeletal immunomodulator of neutrophils that inhibits Rac1.

Authors:  Louie Hendricks; Monowar Aziz; Weng-Lang Yang; Jeffrey Nicastro; Gene F Coppa; Marc Symons; Ping Wang
Journal:  J Surg Res       Date:  2016-09-09       Impact factor: 2.192

6.  Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation.

Authors:  Courtney L Fisher; Lucas B Fallot; Tina C Wan; Robert F Keyes; R Rama Suresh; Amy C Rothwell; Zhan-Guo Gao; John D McCorvy; Brian C Smith; Kenneth A Jacobson; John A Auchampach
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.